期刊文献+

140例三阴乳腺癌病例分析 被引量:9

Retrospective analysis of 140 triple-negative breast cancers
下载PDF
导出
摘要 目的:回顾性分析140例三阴乳腺癌病例,旨在了解该院三阴乳腺癌生存及复发情况。方法:收集中山大学肿瘤防治中心2000—2002年间收治的1125例乳腺癌手术病例,其中140例三阴乳腺癌(其诊断主要基于免疫组化)的病例资料,回顾性分析患者生存情况以及肿瘤复发转移方式。结果:140例三阴乳腺癌患者中位随访时间58个月,5年无病生存率为65.7%,5年总生存率为73.4%。同时期(2000~2002年)该院手术后总的乳腺癌共1125例,5年生存率为86.7%。二者生存率比较(73.4%VS86.7%)有统计学意义。78例绝经前三阴乳腺癌患者5年生存率为75.0%,62例绝经后患者5年生存率为71.3%。有45例三阴乳腺癌发生复发转移,其中17例(37.8%)肝转移,23例(51.1%)肺转移,7例(15.6%)脑转移。结论:与总的乳腺癌比较,三阴乳腺癌的预后更差;绝经前后三阴乳腺癌生存率比较无统计学意义;淋巴结阳性三阴乳腺癌生存差于淋巴结阴性的三阴乳腺癌;与总的乳腺癌比较,三阴乳腺癌复发转移以内脏(肺,肝)转移和脑转移多见。 Objective: Retrospectively analyzed 140 triple-negative cases from Cancer Center of Sun Yat-sen University between 2000 and 2002 years to get the message about survival and recurrence of triple negative breast cancers. Methods: Collected 1 125 postoperative breast cancers from Cancer Center of Sun Yat-sen University between 2000 and 2002 years ( including 140 triple-negative patients, diagnosis mainly based on immunohistochemistry) and analyzed recurrence, metastases and survival of them. Results: As of November 2007, with a median follow-up time of 56.4 + 22.8 months, 78 patients are premenopausal. At 5 years, the triple negative had a disease-free survival rate 65.7% and had a survival rate 73.4%. There were 1 125 postoperative breast cancers which had survival rate 86.7% at 5 years in Cancer Center of Sun Yat-sen University between 2000 and 2002 years. Of 140 triple negative breast cancers,78 premenopausal with the 5-year survival rate 75.0%, 62 post-menopausal with the 5-year survival rate 71.3%. Among 45 recurrent and metastatie (of 140 triple negative breast cancers), Found 17(37.8% ) liver metastatic,23(51.1% )lung metastatic,7 (15.6%) brain metastatic. Conclusion: Triple negative with poorer survival at five years compared with the whole breast cancers over the same time interval (73.4% v 86.7%, respectively). Whether triple negative breast cancers were premenopausal or post-menopausal, the difference of 5-year survival rate was not statistically significant (75.0% v 71.3%, respectively). The triple negative breast cancers with positive lymph node had poorer survival than the triple negative breast cancers with negative lymph node ;Internal organ metastases and brain metastases occurred more easily for triple negative breast cancers.
出处 《赣南医学院学报》 2009年第3期332-335,共4页 JOURNAL OF GANNAN MEDICAL UNIVERSITY
关键词 三阴乳腺癌 基底样亚型 总生存率 无病生存率 Triple-negative breast cancers basal-like subgroup survival rate disease-free survival rate
  • 相关文献

参考文献2

  • 1杨名添,戎铁华,黄植蕃,曾灿光,龙浩,傅剑华,林鹏,王欣,王思愚,王曦,唐军.可手术乳腺癌6263例临床分析[J].癌症,2005,24(3):327-331. 被引量:46
  • 2Shanu Modi,Andrew D. Seidman,Maura Dickler,Mark Moasser,Gabriella D’Andrea,Mary Ellen Moynahan,Jennifer Menell,Katherine S. Panageas,Lee K. Tan,Larry Norton,Clifford A. Hudis. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer[J] 2005,Breast Cancer Research and Treatment(2):157~163 被引量:1

二级参考文献13

  • 1Nab HW, Hop WC, Crommelin MA, et al. Changes in long term prognosis for breast cancer in a Dutch cancer registry[J]. BMJ, 1994,309(6947): 83-86. 被引量:1
  • 2Rutqvist LE, Wallgren A, Nilsson B. Is breast cancer a curable disease? A study of 14,731 women with breast cancer from the Cancer Registry of Norway [J]. Cancer, 1984,53(8): 1793-1800. 被引量:1
  • 3Roses DF. Breast Cancer [M]. New York: Churchill livingstone, 1999: 312. 被引量:1
  • 4Maddox WA, Carpenter JT Jr, Laws HL, et al. A randomized prospective trial of radical (Halsted) mastectomy versus modified radical mastectomy in 311 breast cancer patients [J].Ann Surg, 1983,198(2) :207-212. 被引量:1
  • 5Turner L, Swindell R, Bell WG, et al. Radical versus modified radical mastectomy for breast cancer [J]. Ann R Coil Surg Engl, 1981,63(4) :239-243. 被引量:1
  • 6Martin JK Jr, van Heerden JA, Taylor WF, et al. Is modified radical mastectomy really equivalent to radical mastectomy in treatment of carcinoma of the breast? [J]. Cancer, 1986,57(3) :510-518. 被引量:1
  • 7Early Breast Cancer Trialists Collaborative Group. Effects of radiotherapy and surgery in early breast cancer [J]. N Engl J Med, 1995,333(22): 1444-1455. 被引量:1
  • 8Early Breast Cancer Trialists' Collaborative Group.Polychemotherapy for early breast cancer: an overview of the randomised trials [J]. Lancet, 1998,352(9132) :930-942. 被引量:1
  • 9Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized Trials[J]. Lancet, 1998,351(9114): 1451-1467. 被引量:1
  • 10Fisher B, Jeong JH, Bryant J, et al. Treatment of lymphnode-negative, oestrogen-receptor-positive breast cancer: long term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials [J]. Lancet, 2004,364 ( 9437 ): 858-868. 被引量:1

共引文献45

同被引文献70

  • 1黄红宇,魏云玉.晚期肿瘤患者外周血CTL、Ts及NK细胞免疫表型的联检及临床意义[J].放射免疫学杂志,2006,19(5):439-440. 被引量:4
  • 2陈立慧,朱丽萍,武静.女性激素与乳腺癌[J].中国现代医生,2007,45(07Z):90-91. 被引量:12
  • 3杨光之,皋岚湘,丁华野.乳腺基底细胞样癌[J].诊断病理学杂志,2007,14(4):241-244. 被引量:24
  • 4仲雷,张建国,王永胜.基底细胞样乳腺癌的研究进展(J/CD)[J].中华乳腺癌杂志(电子版),2010,4(6):638-643. 被引量:1
  • 5Naylor PH,Goldstein AL.Thymosin: cyclic nucleotides and T cell differentiation[J] .Life Sci, 1979.259(4):301-10. 被引量:1
  • 6Aqeel Javeed,Muhammad Ashraf.et al.Paclitaxel and immune system[J].European Journal of pharmaceutical Sciences 38(2009)283-290. 被引量:1
  • 7GKonjevic,Vjovic,et a/.CD69 on CD56+ NK cells and response to Chemoimmunotherapy in metestatic melanoma[J].European Journal of chinical investigation (2007)37,887-896. 被引量:1
  • 8Schulof RS,Naylor PH,Sztein MB,et al.Thymic physiology and biochemistry[J].Adv Clin Chem, 1987,26:203-292. 被引量:1
  • 9Ancell CD,Phipp s J, Young L.Thymosin alphal[J].Am J Health Syst Pharm,2001,58( 10):879-888. 被引量:1
  • 10Luigina Romani,Francesco Bistoni,Roberta Gaziano,et al.Thy-mosin alpha I activates dendritic cells for antifimgal Thl resist-ance through Toll-like receptor signaling[J].Blood,2004,103. 被引量:1

引证文献9

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部